PharmaCielo Ltd. is a global company headquartered in Canada and publicly traded on the TSXV. PharmaCielo received its Colombian manufacturing licence in 2016 and has rapidly become a key player in the international medicinal cannabis sector. The company is licensed to produce both CBD-dominant and THC-dominant cannabis extracts.
PharmaCielo Ltd. is the world’s largest licensed cannabis producer. We’re the first company to hold Colombian licences for unrestricted percentages of tetrahydrocannabinol (THC) and cannabidiol (CBD). Our mission is to become the world’s leading supplier of naturally grown and processed, standardized medicinal-grade cannabis oil extracts and related products. PharmaCielo employs a B2B sales and distribution model targeting large channel distributors, finished goods manufacturers, research organizations and pharmaceutical companies. PharmaCielo Ltd. is a global company headquartered in Ontario, Canada, chosen for the country’s standards of financial accountability and regulatory oversight. PharmaCielo Colombia Holdings S.A.S., its wholly owned operating subsidiary, is headquartered in Rionegro, Colombia – a country with outstanding economic conditions, a clear legal framework for cannabis licensing and ideal climatic conditions. The company’s facility, combined with its contract growers’ space, offers access to 110.2 million square feet of open-air greenhouse cultivation capacity.
Located near the equator, Colombia enjoys strong sunlight, fertile soil, ample natural rainfall. The 12-hour day / night light cycle and consistent temperatures year-round readily allow for four cannabis crops per year. Add to these ideal environmental conditions the nation’s decades-long status among the world’s top cut-flower providers, which created both a ready skilled work force and the infrastructure and trade agreements to ship flowers – including cannabis flower products – efficiently and economically to destinations worldwide.
Like Canada, the Colombian government was among the first in the world to recognize and embrace the potential benefits to the country of legalizing and regulating a national medical-cannabis industry. Reflecting its ongoing support for the industry’s progress, in 2020 PharmaCielo was identified as a “Project of National Strategic Interest,” enabling the company to receive immediate support from the Colombian government in recognition of its economic contribution and importance to the nation.